It is thought to be more effective than Mounjaro at helping people lose weight
In the event that impacted product is administered to a patient, there is an increased risk that severe adverse events, such as invasive bacterial infection, including bacterial meningitis, septicemia, and limited adverse events such as fever, chills, malaise, and cutaneous abscess may occur
6.2.2 Phase II clinical trials Based on positive Phase I results, researchers initiated the Phase II clinical trial named Airleaf (NCT05238675) in March 2022 ( Besides the Airleaf study, the research team also initiated two additional Phase II clinical trials, Clairafly (NCT05865886) and Clairleaf (NCT05846230) ( The Clairafly trial focuses on evaluating BI 1291583s safety, tolerability, pharmacodynamics, and pharmacokinetics in adult patients with cystic fibrosis-related bronchiectasis ( The Clairleaf study represents a long-term safety and efficacy evaluation study specifically designed for bronchiectasis patients who previously participated in Airleaf or Clairafly trials ( 6.2.3 Future development plans Additionally, the Phase III randomized, double-blind, placebo-controlled clinical trial named AIRTIVITY (NCT06872892) is planned to commence in June 2025 ( 6.3 HSK31858 clinical studies 6.3.1 Study design and population HSK31858 has completed Phase II clinical studies (SAVE-BE) in Chinese bronchiectasis patients ( 6.3.2 Primary efficacy results Study results showed that both doses of HSK31858 could improve clinical outcomes in bronchiectasis patients: Compared to placebo, both the 20 mg group (hazard ratio = 0.52, 95% confidence interval: 0.340.80
Find out in our updated answer about Supplements and Acid Reflux
Sun-Edelstein C, Mauskop A
